Dynamic models for health economic assessments of pertussis vaccines: What goes around comes around...

Expert Review of Vaccines

Volumn 11, Issue 12, 2012, Pages 1415-1428

  Rozenbaum, Mark H ^a   De Cao, Elisabetta ^a   Westra, Tjalke A ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

booster vaccination; cost effective; dynamic modeling; epidemiology; models; pertussis; transmission; vaccination; whooping cough

Indexed keywords

PERTUSSIS VACCINE;

COST EFFECTIVENESS ANALYSIS; DIPHTHERIA; DISEASE TRANSMISSION; IMMUNITY; IMMUNIZATION; MATHEMATICAL MODEL; PERTUSSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; BORDETELLA PERTUSSIS; COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION, SECONDARY; MODELS, ECONOMIC; PERTUSSIS VACCINE; RISK FACTORS; VACCINATION; WHOOPING COUGH;

EID: 84871593141     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.130     Document Type: Review

References (125)

1. Crowcroft NS, Britto J. Whooping cough-a continuing problem. BMJ 324(7353), 1537-1538 (2002).
2. Westra TA, de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in The Netherlands. Clin. Ther. 32(8), 1479-1495 (2010).
3. Edwards KM. Is pertussis a frequent cause of cough in adolescents and adults? Should routine pertussis immunization be recommended? Clin. Infect. Dis. 32(12), 1698-1699 (2001).
4. Zepp F, Heininger U, Mertsola J et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 11(7), 557-570 (2011).
5. Black S. Epidemiology of pertussis. Pediatr. Infect. Dis. J. 16(Suppl. 4), S85-S89 (1997).
6. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect. Dis. 3(7), 413-418 (2003).
7. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rümke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerging Infect. Dis. 6(4), 348-357 (2000).
8. Wendelboe AM, Njamkepo E, Bourillon A et al.; Infant Pertussis Study Group. Transmission of Bordetella pertussis to young infants. Pediatr. Infect. Dis. J. 26(4), 293-299 (2007).
9. Bisgard KM, Pascual FB, Ehresmann KR et al. Infant pertussis: who was the source? Pediatr. Infect. Dis. J. 23(11), 985-989 (2004).
10. von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect. Dis. 2(12), 744-750 (2002).
11. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18(2), 326-382 (2005).
12. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 115(5), 1422-1427 (2005).
13. Baptista PN, Magalhães V, Rodrigues LC, Rocha MA, Pimentel AM. Source of infection in household transmission of culture-confirmed pertussis in Brazil. Pediatr. Infect. Dis. J. 24(11), 1027-1028 (2005).
14. Baptista PN, Magalhães VS, Rodrigues LC. The role of adults in household outbreaks of pertussis. Int. J. Infect. Dis. 14(2), e111-e114 (2010).
15. Skowronski DM, De Serres G, MacDonald D et al. The changing age and seasonal profile of pertussis in Canada. J. Infect. Dis. 185(10), 1448-1453 (2002).
16. Schellekens J, von König CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr. Infect. Dis. J. 24(Suppl. 5), S19-S24 (2005).
17. Güris D, Strebel PM, Bardenheier B et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin. Infect. Dis. 28(6), 1230-1237 (1999).
18. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE; EUVAC-NET Group. Resurgence of pertussis in Europe. Pediatr. Infect. Dis. J. 24(9), 761-765 (2005).
19. Tozzi AE, Pandolfi E, Celentano LP, Massari M, Salmaso S, Ciofi degli Atti ML; EUVAC-NET Study Group. Comparison of pertussis surveillance systems in Europe. Vaccine 25(2), 291-297 (2007).
20. Pertussis vaccines: WHO position paper. Wkly Epidemiol. Rec. 85(40), 385-400 (2010).
21. Millier A, Aballea S, Annemans L, Toumi M, Quilici S. A critical literature review of health economic evaluations in pertussis booster vaccination. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 71-94 (2012).
22. Rodríguez-Cobo I, Chen YF, Olowokure B, Litchfield I. Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: a systematic review. Vaccine 26(52), 6768-6776 (2008).
23. Postma MJ, de Vries R, Roord J. Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review. Vaccine 27(52), 7242-7243 (2009).
24. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 29(5), 371-386 (2011).
25. Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20(9-10), 1316-1330 (2002).
26. de Vries R, Kretzschmar M, Schellekens JF et al. Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model. PLoS ONE 5(10), e13392 (2010).
27. Coudeville L, Van Rie A, Getsios D, Caro JJ, Crépey P, Nguyen VH. Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS ONE 4(7), e6284 (2009).
28. Rozenbaum MH, De Cao E, Postma MJ. Cost-effectiveness of pertussis booster vaccination in the Netherlands. Vaccine doi:10.1371/journal.pone.0013392 (2012) (Epub ahead of print).
29. Knox EG, Shannon HS. A model basis for the control of whooping cough. Int. J. Epidemiol. 15(4), 544-552 (1986).
30. Grenfell BT, Anderson RM. Pertussis in England and Wales: an investigation of transmission dynamics and control by mass vaccination. Proc. R Soc. Lond. B Biol. Sci. 236(1284), 213-252 (1989).
31. Hethcote HW. An age-structured model for pertussis transmission. Math. Biosci. 145(2), 89-136 (1997).
32. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 22(23-24), 3154-3165 (2004).
33. Hethcote HW, Horby P, McIntyre P. Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 22(17-18), 2181-2191 (2004).
34. Coudeville L, van Rie A, Andre P. Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies. Epidemiol. Infect. 136(5), 604-620 (2008).
35. Hethcote HW. Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations. Math. Biosci. 158(1), 47-73 (1999).
36. van Boven M, de Melker HE, Schellekens JF, Kretzschmar M. Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands. Math. Biosci. 164(2), 161-182 (2000).
37. van Boven M, de Melker HE, Schellekens JF, Kretzschmar M. A model based evaluation of the 1996-7 pertussis epidemic in The Netherlands. Epidemiol. Infect. 127(1), 73-85 (2001).
38. Rozenbaum MH, De Vries R, LE HH, Postma MJ. Modelling the impact of extended vaccination strategies on the epidemiology of pertussis. Epidemiol. Infect. 140(8), 1503-1514 (2012).
39. Knox EG, Shannon HS. A model basis for the control of whooping cough. Int. J. Epidemiol. 15(4), 544-552 (1986).
40. Grenfell BT, Anderson RM. Pertussis in England and Wales: an investigation of transmission dynamics and control by mass vaccination. Proc. R. Soc. Lond., B, Biol. Sci. 236(1284), 213-252 (1989).
41. Fabricius G, Bergero PE, Ormazabal ME, Maltz AL, Hozbor DF. Modelling pertussis transmission to evaluate the effectiveness of an adolescent booster in Argentina. Epidemiol. Infect. 1-17 (2012).
42. Luz PM, Codeço CT, Werneck GL, Struchiner CJ. A modelling analysis of pertussis transmission and vaccination in Rio de Janeiro, Brazil. Epidemiol. Infect. 134(4), 850-862 (2006).
43. Anderson RM, May RM. Infectious Diseases of Humans. Oxford University Press, Oxford, UK (1991).
44. Anderson RM, May RM. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J. Hyg. (Lond). 94(3), 365-436 (1985).
45. Kretzschmar M, Teunis PF, Pebody RG. Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries. PLoS Med. 7(6), e1000291 (2010).
46. Wearing HJ, Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog. 5(10), e1000647 (2009).
47. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24(Suppl. 5), S58-S61 (2005).
48. de Greeff SC, Lugnér AK, van den Heuvel DM, Mooi FR, de Melker HE. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine 27(13), 1932-1937 (2009).
49. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin. Infect. Dis. 39(1), 20-28 (2004).
50. Ortega-Sanchez IR, Lee GM, Jacobs RJ et al.; Working Group on Leading Economic Issues for New Vaccine for Adolescents. Projected cost-effectiveness of new vaccines for adolescents in the United States. Pediatrics 121(Suppl. 1), S63-S78 (2008).
51. Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics 115(6), 1675-1684 (2005).
52. Lee GM, Murphy TV, Lett S et al. Cost effectiveness of pertussis vaccination in adults. Am. J. Prev. Med. 32(3), 186-193 (2007).
53. Caro J, Denis G, Coudeville L, Van Rie A. Pertussis in adolescents and adults: should we accept the results? Pediatrics 116(5), 1263; author reply 1263-1263; author reply 1264 (2005).
54. Broder KR, Cortese MM, Iskander JK et al.; Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55(RR-3), 1-34 (2006).
55. De Serres G, Shadmani R, Duval B et al. Morbidity of pertussis in adolescents and adults. J. Infect. Dis. 182(1), 174-179 (2000).
56. Westra TA, Parouty M, Brouwer WB et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health 15(3), 562-567 (2012).
57. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J. Infect. 53(2), 106-113 (2006).
58. Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am. J. Epidemiol. 164(10), 936-944 (2006).
59. Edwards KM, Decker M. Pertussis vaccine. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Eds). Saunders, PA, USA, 471-528 (2012).
60. Pertussis vaccines: WHO position paper-recommendations. Vaccine 29(13), 2355-2356 (2011).
61. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect. Dis. 8(11), 727-733 (2008).
62. de Vries R. Health economics of Interventions aimed at Infectious Diseases; dynamic modeling inevitable for reliable decision making. ORO Grafisch Project Management, Koekange, The Netherlands (2012).
63. Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev. Vaccines 7(6), 753-782 (2008).
64. de Greeff SC, de Melker HE, van Gageldonk PG et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS ONE 5(12), e14183 (2010).
65. Lavine JS, King AA, Bjørnstad ON. Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proc. Natl Acad. Sci. USA 108(17), 7259-7264 (2011).
66. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect. Dis. 7(9), 614-624 (2007).
67. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged 12 months-Advisory Committee on Immunization Practices (ACIP 2011. MMWR Morb. Mortal. Wkly Rep. 60(41), 1424-1426, 2011.
68. Grenfell B. Boosting understanding of pertussis outbreaks. Proc. Natl Acad. Sci. USA 108(18), 7279-7280 (2011).
69. Lavine JS, Bjørnstad ON, de Blasio BF, Storsaeter J. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine 30(3), 544-551 (2012).
70. Wendelboe AM, Hudgens MG, Poole C, Van Rie A. Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants. Emerg. Themes Epidemiol. 4, 15 (2007).
71. de Greeff SC, Mooi FR, Westerhof A et al. Pertussis disease burden in the household: how to protect young infants. Clin. Infect. Dis. 50(10), 1339-1345 (2010).
72. Mossong J, Hens N, Jit M et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5(3), e74 (2008).
73. Rohani P, Zhong X, King AA. Contact network structure explains the changing epidemiology of pertussis. Science 330(6006), 982-985 (2010).
74. Rashid H, Khandaker G, Booy R. Vaccination and herd immunity: what more do we know? Curr. Opin. Infect. Dis. 25(3), 243-249 (2012).
75. Fine P, Eames K, Heymann DL. 'Herd immunity': a rough guide. Clin. Infect. Dis. 52(7), 911-916 (2011).
76. Fine PE. Herd immunity: history, theory, practice. Epidemiol. Rev. 15(2), 265-302 (1993).
77. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360(9334), 678-682 (2002).
78. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med. 58, 9-20 (1965).
79. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20(19-20), 2500-2507 (2002).
80. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J. Infect. Dis. 191(12), 2002-2007 (2005).
81. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med. Decis. Making 23(1), 76-82 (2003).
82. Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 319(7223), 1462-1467 (1999).
83. Rozenbaum MH, Verweel G, Folkerts DK et al. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands. Int. J. STD AIDS 19(10), 668-675 (2008).
84. Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged or =65 years in the Netherlands. Clin. Ther. 32(8), 1517-1532 (2010).
85. Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ; Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 11, 462 (2011).
86. Postma MJ, Jit M, Rozenbaum MH, Standaert B, Tu HA, Hutubessy RC. Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. BMC Med. 9, 84 (2011).
87. Westra TA, Rozenbaum MH, Rogoza RM et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J. Infect. Dis. 204(3), 377-384 (2011).
88. Meijboom MJ, Rozenbaum MH, Benedictus A et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. Vaccine 30(31), 4691-4700 (2012).
89. Rozenbaum MH, Sanders EA, van Hoek AJ et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 340, c2509 (2010).
90. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc. Natl Acad. Sci. USA 94(12), 6571-6576 (1997).
91. Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev. Vaccines 10(2), 187-199 (2011).
92. van Gils EJ, Veenhoven RH, Hak E et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 302(2), 159-167 (2009).
93. Ghaffar F, Barton T, Lozano J et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin. Infect. Dis. 39(7), 930-938 (2004).
94. O'Brien KL, Millar EV, Zell ER et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196(8), 1211-1220 (2007).
95. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180(4), 1171-1176 (1999).
96. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat. Med. 18(23), 3263-3282 (1999).
97. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med. Decis. Making 26(5), 434-446 (2006).
98. Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev. Vaccines 2(5), 649-660 (2003).
99. Welte R, Postma M, Leidl R, Kretzschmar M. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex. Transm. Dis. 32(8), 474-483 (2005).
100. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat. Med. 18(23), 3263-3282 (1999).
101. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype-and clone-specific differences in invasive disease potential. J. Infect. Dis. 187(9), 1424-1432 (2003).
102. Trotter CL, Waight P, Andrews NJ et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996-2006. J. Infect. 60(3), 200-208 (2010).
103. Rozenbaum MH, Hoek AJ, Hak E, Postma MJ. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine 28(12), 2367-2369 (2010).
104. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect. Dis. 10, 90 (2010).
105. Choi YH, Jit M, Gay N et al. 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement? PLoS ONE 6(10), e26190 (2011).
106. de Melker HE, Conyn-van Spaendonck MA, Rümke HC, van Wijngaarden JK, Mooi FR, Schellekens JF. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerging Infect. Dis. 3(2), 175-178 (1997).
107. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr. Infect. Dis. J. 22(1), 22-27 (2003).
108. Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995-2005-trends by region and age group. Commun. Dis. Intell. 31(2), 205-215 (2007).
109. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr. Infect. Dis. J. 27(3), 218-223 (2008).
110. Kowalzik F, Barbosa AP, Fernandes VR et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr. Infect. Dis. J. 26(3), 238-242 (2007).
111. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheriapertussis vaccine: effect on maternal and neonatal serum antibody levels. Am. J. Obstet. Gynecol. 204(4), 334.e1-334.e5 (2011).
112. Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr. Infect. Dis. J. 30(7), 608-610 (2011).
113. Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J. Infect. Dis. 161(3), 487-492 (1990).
114. Glezen WP, Alpers M. Maternal immunization. Clin. Infect. Dis. 28(2), 219-224 (1999).
115. Simister NE. Placental transport of immunoglobulin G. Vaccine 21(24), 3365-3369 (2003).
116. Mooi FR, van Loo IH, van Gent M et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerging Infect. Dis. 15(8), 1206-1213 (2009).
117. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am. J. Reprod. Immunol. 36(5), 248-255 (1996).
118. Englund JA, Anderson EL, Reed GF et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 96(3 Pt 2), 580-584 (1995).
119. Munoz FM, Englund JA. Vaccines in pregnancy. Infect. Dis. Clin. North Am. 15(1), 253-271 (2001).
120. Siegrist CA. Neonatal and early life vaccinology. Vaccine 19(25-26), 3331-3346 (2001).
121. Siegrist CA. Vaccination in the neonatal period and early infancy. Int. Rev. Immunol. 19(2-3), 195-219 (2000).
122. Bechini A, Tiscione E, Boccalini S, Levi M, Bonanni P. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations. Vaccine 30(35), 5179-5190 (2012).
123. Halperin SA. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr. Infect. Dis. J. 24(Suppl. 6), S141-S146 (2005).
124. Healy CM, Rench MA, Baker CJ. Implementation of cocooning against pertussis in a high-risk population. Clin. Infect. Dis. 52(2), 157-162 (2011).
125. Miller BL, Kretsinger K, Euler GL, Lu PJ, Ahmed F. Barriers to early uptake of tetanus, diphtheria and acellular pertussis vaccine (Tdap) among adults-United States, 2005-2007. Vaccine 29(22), 3850-3856 (2011).